摘要
Abstract
Objective To investigate the influence of Shenyi Capsule combined with the neoadjuvant chemotherapy on the operative risk and prognosis in the patients with the progressive stage of esophageal carcinoma. Methods Totally 207 patients with the progressive stage of esophageal carcinoma treated in the general department of the hospital from January 2012 to January 2014 were selected and randomly divided into the observation group(99 cases) and the control group(108 cases). The patients of the two groups received the preoperative chemotherapeutic regimen of paclitaxel and cisplatinum ﹢ radical operation ﹢ paclitaxel and cisplatinum regimen after postoperative chemotherapy,while the patients in the treatment group was added with Shenyi Capsule. All the patients were given the symptomatic support treatment. The differences in the operation situation,effectiveness of treatment,recurrence rate and survival rate were compared between the two groups. The occurrence situation of adverse reactions was recorded and the safety analysis was per-formed. Results Compare with the contorl group,the operation situation and treatment effectiveness in the treatment group were signifi-cantly better( P ﹤ 0. 05 ),the recurrence rate was significantly lower( P﹤ 0. 05 ),the 3-year survival rate was significantly higher ( P ﹤ 0. 05) and the occurrence rate of chemotherapeutic adverse reactions was significantly lower ( P ﹤ 0. 05 ) . Conclusion Shenyi Capsule combined with the routine chemotherapy for treating the progressive stage of esophageal carcinoma can increase the clinical cu-rative effect and the long term survival rate,improve the perioperative situation,reduce the occurrence rate of chemotherapeutic drugs and is worthy of clinical promotion.关键词
参一胶囊/食管癌/进展期/手术/风险/预后Key words
Shenyi Capsule/esophageal cancer/progressive stage/surgery/risk/prognosis分类
医药卫生
